Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange

A. C M Figueira, D. M. Saidemberg, P. C T Souza, L. Martínez, Thomas (Tom) Scanlan, J. D. Baxter, M. S. Skaf, M. S. Palma, P. Webb, I. Polikarpov

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Thyroid hormone receptors (TRs) are ligand-gated transcription factors with critical roles in development and metabolism. Although x-ray structures of TR ligand-binding domains (LBDs) with agonists are available, comparable structures without ligand (apo-TR) or with antagonists are not. It remains important to understand apo-LBD conformation and the way that it rearranges with ligands to develop better TR pharmaceuticals. In this study, we conducted hydrogen/deuterium exchange on TR LBDs with or without agonist (T3) or antagonist (NH3). Both ligands reduce deuterium incorporation into LBD amide hydrogens, implying tighter overall folding of the domain. As predicted, mass spectroscopic analysis of individual proteolytic peptides after hydrogen/ deuterium exchange reveals that ligand increases the degree of solvent protection of regions close to the buried ligand-binding pocket. However, there is also extensive ligand protection of other regions, including the dimer surface at H10-H11, providing evidence for allosteric communication between the ligand-binding pocket and distant interaction surfaces. Surprisingly, Cterminal activation helix H12, which is known to alter position with ligand, remains relatively protected from solvent in all conditions suggesting that it is packed against the LBD irrespective of the presence or type of ligand. T3, but not NH3, increases accessibility of the upper part of H3-H5 to solvent, and we propose that TR H12 interacts with this region in apo-TR and that this interaction is blocked by T3 but not NH3.Wepresent data from site-directed mutagenesis experiments and molecular dynamics simulations that lend support to this structural model of apo-TR and its ligand-dependent conformational changes. (Molecular Endocrinology 25: 15-31, 2011).

Original languageEnglish (US)
Pages (from-to)15-31
Number of pages17
JournalMolecular Endocrinology
Volume25
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Thyroid Hormone Receptors
Deuterium
Hydrogen
Ligands
Endocrinology
Structural Models
Molecular Dynamics Simulation
Site-Directed Mutagenesis

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Figueira, A. C. M., Saidemberg, D. M., Souza, P. C. T., Martínez, L., Scanlan, T. T., Baxter, J. D., ... Polikarpov, I. (2011). Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange. Molecular Endocrinology, 25(1), 15-31. https://doi.org/10.1210/me.2010-0202

Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange. / Figueira, A. C M; Saidemberg, D. M.; Souza, P. C T; Martínez, L.; Scanlan, Thomas (Tom); Baxter, J. D.; Skaf, M. S.; Palma, M. S.; Webb, P.; Polikarpov, I.

In: Molecular Endocrinology, Vol. 25, No. 1, 01.2011, p. 15-31.

Research output: Contribution to journalArticle

Figueira, ACM, Saidemberg, DM, Souza, PCT, Martínez, L, Scanlan, TT, Baxter, JD, Skaf, MS, Palma, MS, Webb, P & Polikarpov, I 2011, 'Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange', Molecular Endocrinology, vol. 25, no. 1, pp. 15-31. https://doi.org/10.1210/me.2010-0202
Figueira, A. C M ; Saidemberg, D. M. ; Souza, P. C T ; Martínez, L. ; Scanlan, Thomas (Tom) ; Baxter, J. D. ; Skaf, M. S. ; Palma, M. S. ; Webb, P. ; Polikarpov, I. / Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange. In: Molecular Endocrinology. 2011 ; Vol. 25, No. 1. pp. 15-31.
@article{e30c8ab1bfe74c3095ef765fa427376c,
title = "Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange",
abstract = "Thyroid hormone receptors (TRs) are ligand-gated transcription factors with critical roles in development and metabolism. Although x-ray structures of TR ligand-binding domains (LBDs) with agonists are available, comparable structures without ligand (apo-TR) or with antagonists are not. It remains important to understand apo-LBD conformation and the way that it rearranges with ligands to develop better TR pharmaceuticals. In this study, we conducted hydrogen/deuterium exchange on TR LBDs with or without agonist (T3) or antagonist (NH3). Both ligands reduce deuterium incorporation into LBD amide hydrogens, implying tighter overall folding of the domain. As predicted, mass spectroscopic analysis of individual proteolytic peptides after hydrogen/ deuterium exchange reveals that ligand increases the degree of solvent protection of regions close to the buried ligand-binding pocket. However, there is also extensive ligand protection of other regions, including the dimer surface at H10-H11, providing evidence for allosteric communication between the ligand-binding pocket and distant interaction surfaces. Surprisingly, Cterminal activation helix H12, which is known to alter position with ligand, remains relatively protected from solvent in all conditions suggesting that it is packed against the LBD irrespective of the presence or type of ligand. T3, but not NH3, increases accessibility of the upper part of H3-H5 to solvent, and we propose that TR H12 interacts with this region in apo-TR and that this interaction is blocked by T3 but not NH3.Wepresent data from site-directed mutagenesis experiments and molecular dynamics simulations that lend support to this structural model of apo-TR and its ligand-dependent conformational changes. (Molecular Endocrinology 25: 15-31, 2011).",
author = "Figueira, {A. C M} and Saidemberg, {D. M.} and Souza, {P. C T} and L. Mart{\'i}nez and Scanlan, {Thomas (Tom)} and Baxter, {J. D.} and Skaf, {M. S.} and Palma, {M. S.} and P. Webb and I. Polikarpov",
year = "2011",
month = "1",
doi = "10.1210/me.2010-0202",
language = "English (US)",
volume = "25",
pages = "15--31",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange

AU - Figueira, A. C M

AU - Saidemberg, D. M.

AU - Souza, P. C T

AU - Martínez, L.

AU - Scanlan, Thomas (Tom)

AU - Baxter, J. D.

AU - Skaf, M. S.

AU - Palma, M. S.

AU - Webb, P.

AU - Polikarpov, I.

PY - 2011/1

Y1 - 2011/1

N2 - Thyroid hormone receptors (TRs) are ligand-gated transcription factors with critical roles in development and metabolism. Although x-ray structures of TR ligand-binding domains (LBDs) with agonists are available, comparable structures without ligand (apo-TR) or with antagonists are not. It remains important to understand apo-LBD conformation and the way that it rearranges with ligands to develop better TR pharmaceuticals. In this study, we conducted hydrogen/deuterium exchange on TR LBDs with or without agonist (T3) or antagonist (NH3). Both ligands reduce deuterium incorporation into LBD amide hydrogens, implying tighter overall folding of the domain. As predicted, mass spectroscopic analysis of individual proteolytic peptides after hydrogen/ deuterium exchange reveals that ligand increases the degree of solvent protection of regions close to the buried ligand-binding pocket. However, there is also extensive ligand protection of other regions, including the dimer surface at H10-H11, providing evidence for allosteric communication between the ligand-binding pocket and distant interaction surfaces. Surprisingly, Cterminal activation helix H12, which is known to alter position with ligand, remains relatively protected from solvent in all conditions suggesting that it is packed against the LBD irrespective of the presence or type of ligand. T3, but not NH3, increases accessibility of the upper part of H3-H5 to solvent, and we propose that TR H12 interacts with this region in apo-TR and that this interaction is blocked by T3 but not NH3.Wepresent data from site-directed mutagenesis experiments and molecular dynamics simulations that lend support to this structural model of apo-TR and its ligand-dependent conformational changes. (Molecular Endocrinology 25: 15-31, 2011).

AB - Thyroid hormone receptors (TRs) are ligand-gated transcription factors with critical roles in development and metabolism. Although x-ray structures of TR ligand-binding domains (LBDs) with agonists are available, comparable structures without ligand (apo-TR) or with antagonists are not. It remains important to understand apo-LBD conformation and the way that it rearranges with ligands to develop better TR pharmaceuticals. In this study, we conducted hydrogen/deuterium exchange on TR LBDs with or without agonist (T3) or antagonist (NH3). Both ligands reduce deuterium incorporation into LBD amide hydrogens, implying tighter overall folding of the domain. As predicted, mass spectroscopic analysis of individual proteolytic peptides after hydrogen/ deuterium exchange reveals that ligand increases the degree of solvent protection of regions close to the buried ligand-binding pocket. However, there is also extensive ligand protection of other regions, including the dimer surface at H10-H11, providing evidence for allosteric communication between the ligand-binding pocket and distant interaction surfaces. Surprisingly, Cterminal activation helix H12, which is known to alter position with ligand, remains relatively protected from solvent in all conditions suggesting that it is packed against the LBD irrespective of the presence or type of ligand. T3, but not NH3, increases accessibility of the upper part of H3-H5 to solvent, and we propose that TR H12 interacts with this region in apo-TR and that this interaction is blocked by T3 but not NH3.Wepresent data from site-directed mutagenesis experiments and molecular dynamics simulations that lend support to this structural model of apo-TR and its ligand-dependent conformational changes. (Molecular Endocrinology 25: 15-31, 2011).

UR - http://www.scopus.com/inward/record.url?scp=78650854003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650854003&partnerID=8YFLogxK

U2 - 10.1210/me.2010-0202

DO - 10.1210/me.2010-0202

M3 - Article

VL - 25

SP - 15

EP - 31

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 1

ER -